PTA-PVR: Dr. Hönle AG: Release according to Article 40, Section 1 of the WpHG
Gilching (pta018/02.01.2025/11:30) – Release of Voting Rights Announcement
Gilching (pta018/02.01.2025/11:30) – Release of Voting Rights Announcement
Gilching (pta008/06.12.2024/08:40) – According to preliminary and unaudited figures, the Hönle Group achieved the following results in the 2023/24 financial year:
Gilching (pta014/21.11.2024/10:15) – The Management Board forecasted sales of around €100 million and a positive operating result (EBIT) for the Hönle Group for the 2023/24 financial year. Based on current knowledge, the Management Board assumes that the Hönle Group achieved a positive operating result (adjusted EBIT) in the 2023/24 financial year with sales of around €98 million.
Gilching (pta024/20.11.2024/16:50) – Dr. Hönle AG announces that the following financial reports shall be disclosed:
Gilching (pta022/07.08.2024/16:10) – Release of Voting Rights Announcement
Gilching (pta020/07.08.2024/16:05) – Release of Voting Rights Announcement
Gilching (pta006/07.08.2024/08:40) – – Sales of €72.1 million are 9.6% below the previous year’s figures
Gilching (pta021/06.08.2024/11:25) – On 2 August 2024, the Supervisory Board of Dr. Hönle AG appointed Robert Stark as a member of the Management Board of Dr. Hönle AG effective 1 October 2024. Robert Stark will assume the post of Chief Financial Officer. Dr. Markus Arendt was appointed Chief Executive Officer of Dr. Hönle AG as part of the expansion of the Management Board from one to two members. The expansion of the Management Board to two members thus completes the reorganisation of the Management Board in terms of personnel.
Gilching (pta009/08.05.2024/08:10) – * Weakness in machinery and plant engineering and project postponements in the solar industry and electromobility business lead to a 10.1% decline in sales to € 48.1 million * Operating result is € –0.1 million after € 3.7 million in the previous year * Recovery expected in the second half of the financial year * Outlook for the 2023/24 financial year: sales of around €100 million and positive operating result (EBIT)
Gilching (pta010/07.05.2024/08:55) – As planned, Dr. Markus Arendt took up his position as CEO of Dr. Hönle AG on May 1, 2024. He succeeds Dr. Franz Richter, who was appointed to the Executive Board by the Supervisory Board for a year. Franz Richter returns to the Supervisory Board and takes over the chairmanship again. Mr. Niklas Friedrichsen took over the chairmanship of the supervisory board during the time of the assignment.